알츠하이머

A new brain imaging study has found that recalling facts and personal experiences activates nearly identical neural networks, challenging long-held views on memory systems. Researchers from the University of Nottingham and University of Cambridge used fMRI scans on 40 participants to compare these memory types. The results, published in Nature Human Behaviour, suggest a rethink in how memory is studied and could inform treatments for Alzheimer's and dementia.

2026년 02월 02일 AI에 의해 보고됨

A large study of nearly 2 million older adults has found that cerebral amyloid angiopathy, a condition where amyloid proteins build up in brain blood vessels, sharply increases the risk of dementia. Within five years of diagnosis, people with this disorder were four times more likely to develop dementia than those without it, even absent a history of stroke. The findings, drawn from Medicare records, underscore the need for early cognitive screening in affected individuals.

As the population ages, more people are affected by memory diseases like Alzheimer's. However, research in the field is progressing slowly, and only about half of those affected receive the available treatment.

2026년 01월 05일 AI에 의해 보고됨

European scientists have developed a preliminary method to identify Alzheimer's using a drop of dried blood from a finger, achieving 86% accuracy in detecting amyloid pathology. The study, validated in 337 patients from several countries, is published in Nature Medicine and aims to simplify early diagnosis of this disease affecting over 50 million people worldwide.

A Swedish study suggests that consuming more high-fat cheese could lower dementia risk by 13%, based on data from nearly 30,000 people followed for 25 years. However, experts caution that it is an observational analysis without proof of causality. Critics highlight potential confounders and the importance of factors like blood pressure and weight control.

2025년 12월 12일 AI에 의해 보고됨

알츠하이머 시험이 암 연구에서 영감을 받은 다중 표적 접근으로 전환 중이며, Novo Nordisk의 세마글루타이드 실패에도 불구하고. Eli Lilly의 Kisunla와 Eisai 및 Biogen의 Leqembi 두 약물만이 진행을 늦추기 위해 널리 승인됨. 이러한 진화는 뇌 퇴화 질환을 복잡한 시스템으로 간주하며, 전 세계적 영향 속에서 이를 멈추는 새로운 방법을 모색함.